
ARDX
Healthcare · Biotechnology · $776.7M market cap
$3.09-0.03 (-1.0%)Nov 13, 4:29 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -72.7% over 90 days · 30-day revisions 1 up, 2 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 3, 2026 | After the close | -0.02 | 0.00 | +100.0% |
| Aug 6, 2026 | After the close | -0.05 | -0.07 | -40.0% |
| Apr 30, 2026 | After the close | -0.14 | -0.15 | -7.1% |
| Mar 11, 2026 | Time not confirmed | -0.02 | -0.00 | +91.4% |
| Oct 30, 2025 | After the close | -0.07 | -0.00 | +94.3% |
| Aug 4, 2025 | After the close | -0.14 | -0.08 | +42.9% |
| May 1, 2025 | After the close | -0.07 | -0.17 | -142.9% |
| Feb 20, 2025 | Before the open | -0.00 | 0.02 | +2957.1% |
| Oct 31, 2024 | After the close | -0.05 | -0.00 | +93.2% |
| Aug 1, 2024 | After the close | -0.11 | -0.07 | +36.4% |
| May 2, 2024 | After the close | -0.16 | -0.11 | +31.3% |
| Feb 22, 2024 | After the close | -0.09 | -0.12 | -33.3% |
| Oct 31, 2023 | Before the open | -0.11 |
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx,…
| 0.03 |
| +127.3% |
| Aug 2, 2023 | Before the open | -0.11 | -0.08 | +27.3% |
| May 3, 2023 | After the close | -0.10 | -0.13 | -30.0% |
| Mar 2, 2023 | After the close | -0.02 | 0.06 | +400.0% |
| Nov 3, 2022 | After the close | -0.17 | -0.14 | +17.6% |
| Aug 4, 2022 | After the close | -0.20 | -0.19 | +5.0% |
| May 5, 2022 | After the close | -0.23 | -0.21 | +8.7% |
| Feb 28, 2022 | After the close | -0.30 | -0.31 | -3.3% |
| Nov 12, 2021 | Before the open | -0.35 | -0.42 | -20.0% |
| Aug 13, 2021 | Before the open | -0.37 | -0.45 | -21.6% |
| May 6, 2021 | Before the open | -0.34 | -0.34 | 0.0% |
| Mar 8, 2021 | Before the open | -0.26 | -0.32 | -23.1% |
| Nov 5, 2020 | Before the open | -0.30 | -0.20 | +33.3% |
| Aug 6, 2020 | After the close | -0.25 | -0.28 | -12.0% |
| May 7, 2020 | After the close | -0.25 | -0.25 | 0.0% |
| Mar 6, 2020 | After the close | -0.33 | -0.27 | +18.2% |
| Nov 6, 2019 | After the close | -0.37 | -0.37 | 0.0% |
| Aug 9, 2019 | Before the open | -0.38 | -0.41 | -7.9% |
| May 7, 2019 | After the close | -0.39 | -0.42 | -7.7% |
| Mar 6, 2019 | After the close | -0.41 | -0.45 | -9.8% |
| Nov 7, 2018 | After the close | -0.43 | -0.39 | +9.3% |
| Aug 7, 2018 | After the close | -0.44 | -0.42 | +4.5% |
| May 8, 2018 | After the close | -0.46 | -0.36 | +21.7% |
| Mar 14, 2018 | After the close | -0.41 | 0.21 | +151.2% |